natgillin/translations-raw huggingface dataset:
The method of claim 5, wherein the solvent of the RIS is water or an organic solvent selected from the group consisting of petrol, ligroin, white spirit, kerosene and naphtha. 
Postupak prema patentnom zahtjevu 13, naznačen time, da otapalo za RTS jest voda ili organsko otapalo odabrano iz skupine koja se sastoji od benzina, ligroina, terpentina, kerozina i nafte.
The dosage form of claim 1 which comprises, relative to the weight of the dosage form, from 5 to 30 % by weight of ritonavir and lopinavir, from 50 to 85 % by weight of said water-soluble polymer, from 2 to 20 % by weight of said surfactant, and from 0 to 15 % by weight of additives. 
Dozirni oblik prema bilo kojem od prethodnih zahtjeva, koji sadrži, u odnosu na težinu dozirnog oblika, od 5 do 30% težine inhibitora proteaze HIV-a, od 2 do 20% težine surfaktanta i od 0 do 15% težine aditiva.
● an inhibitor of neutrophil serine proteases, for example neutrophil elastase or proteinase 3. 
* inhibitor neutrofil serin proteaza, na primjer neutrofilne elastaze ili proteinaze 3.
Floor panel according to any of the preceding claims, characterized in that the lock-up body (14) is provided in the proximal side of the female part (9). 
Podni panel sukladno bilo kojem od prethodnih zahtjeva, naznačen time što je navedeni element zaključavanja (12) osiguran na navedenom muškom dijelu (8).
R2, R4 and R5 are independently an optionally substituted 5-12 membered carbocyclic ring, heterocyclic ring, aryl or heteroaryl; or R4 is H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, or wherein P is C or N and ring E together with P form an optionally substituted 5-12 membered monocyclic or fused ring; 
, R4 i R5 su neovisno opcijski supstituiran 5-12 člani karbociklički prsten, heterociklički prsten, aril ili heteroaril; ili R4 je H, C1-6alkil, C2-6alkenil, C2-6alkinil, ili [image] gdje P je C ili N, a prsten E zajedno s P tvore opcijski supstituiran 5-12 člani monociklički ili sjedinjen prsten;
A solution of the crude alkene (10.87 g, 36.11 mmol) from Example 1B in dry THF (52 ml) at room temperature was treated with 1M borane-THF (155.6 ml, 155.6 mmol, 4.30 eq) added in a dropwise manner. 
2R3R11bS Otopina sirovog alkena (10.87 g, 36.11 mmol) iz Primjera 1B u suhom THF (52 ml) na sobnoj temperaturi se tretira s IM boran-THF (155.6 ml, 155.6 mmol, 4.30 ekvivalenta) koji se dodaje kapanjem.
PCT/GB2005/000464 demonstrate receptor binding profiles broadly similar to the receptor binding profiles of atypical antipsychotic agents. 
PCT/GB2005/000464 pokazuje profil vezivanja receptora uvelike sličan profilima vezivanja receptora atipičnih antipsihotičnih sredstava.
a group of formula -Het-Alk- wherein Alk is a (C1-C8)alkanediyl group and is linked to NR3, and Het is a heterocycle optionally substituted by a (C1-C6)alkyl group and containing at least one nitrogen atom, said nitrogen atom being linked to L, or 
skupina formule -Het-Alk- gdje Alk jest (C1-C8)alkandiilna skupina i spojena je za NR3, te je Het heterociklil opcionalno supstituiran s (C1-C6)alkilnom skupinom i sadrži najmanje jedan dušikov atom, rečeni dušikov atom vezan je za L, ili
Accordingly, in one aspect the cell according to the present invention comprises an expression cassette comprising the polynucleotide encoding the protein of interest. 
Stanica prema zahtjevu 19, naznačena time što stanica sadrži ekspresijsku kasetu ili vektor koji sadrži polinukleotidnu sekvencu koja kodira protein od interesa.
Removal of solvent under reduced pressure yields 3-oxo-cyclopentane-1,1-dicarboxylic acid ethyl ester. 
Uklanjanjem otapala pod sniženim tlakom dobiva se etilni ester 3-oksociklopentan-1,1-dikarboksilne kiseline.
preferably 30 to 95% by weight, and still more preferably 40 to 90% by weight 
0 do 30% po težini, pri čemu sadržaj klinker faza iznosi do 100%.
The solid formulation according to any of claims 2 to 7, characterized in that the flow regulator is selected from the group consisting of silica, preferably colloidal anhydrous silica, calcium silicate, magnesium silicate and talc. 
Čvrsta formulacija prema bilo kojem od patentnih zahtjeva 2 do 8, naznačena time, da je regulator protočnosti odabran iz skupine koja se sastoji od silicijevog dioksida, poželjno koloidnog bezvodnog silicijevog dioksida, kalcijevog silikata, magnezijevog silikata i talka.
The vaccine of claim 1, wherein the recombinant Mycobacterium bovis cell does not carry an antibiotic resistance gene. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1, naznačena time što rekombinantna Mycobacterium bovis stanica ne nosi gen za rezistenciju na antibiotike.
The solid dispersion of claim 1, wherein the N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide is present in an amount of from about 10% by weight to about 80% by weight. 
Kruta disperzija prema bilo kojem od zahtjeva 1 do 7, naznačena time da je N-[2,4-bis(1,1-dimetiletil)-5hidroksfenil|-1,4-dihidro-4-oksokinolin-3-karboksamid prisutan u količini od 10% masenih do 80% masenih.
Means according to claims 1 or 2, characterized in that the upper surface of the collector (2) comprises holes allowing possible air gathered in the collector (2) to escape. 
Sredstva prema zahtjevu 1 ili 2, naznačena time što gornja površina sabirnika (2) sadrži provrte koji omogućavaju izlazak mogućeg zraka nakupljenog u sabirniku (2).
The anti-CD20 antibody formulation for use according to claim 1, wherein the sodium chloride is present in an amount of 51mM. 
Formulacija protutijela an4-CD20 za uporabu prema zahtjevu 1, naznačena time, da je natrijev klorid prisutan u količini od 51 mM.
A method according to claim 1, wherein said clusters (21) have a face-centred cubic crystalline structure, fcc [110]. 
Metoda prema zahtjevu 1, naznačena time da klasteri (21) imaju plošno centirane kubične kristalne strukture (fcc)
The compound of formula (I) as defined in claim 13 for use according to claim 13, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, or combinations thereof; or, wherein the second agent is allopurinol, febuxostat, FYX-051, or combinations thereof. 
Spoj formule (I) kao što je utvrđeno u patentnim zahtjevima 1-9 za uporabu sukladno patentnom zahtjevu 10, naznačeno time da, drugo sredstvo je inhibitor URAT 1, inhibitor ksantin oksidaze, ksantin dehidrogenaza, inhibitor ksantin oksidoreduktaze ili njihove kombinacije; ili, pri čemu, drugo sredstvo je alopurinol, febuksostat, FYX-051 ili njihove kombinacije.
the first fragment has a first proximal end; 
(ili) proksimalni kraj prvog fragmenta se nalazi unutar prvog ponavljanog dijela;
The pharmaceutical composition of statement 11, wherein said composition comprises at least one viscosity-increasing agent that reduces or prevents postnasal drip of said composition into the pharynx upon intranasal administration of said composition. The pharmaceutical composition of statement 13, wherein said viscosity-increasing agent is selected from the group consisting of a polyvinylpyrrolidone, a cellulose derivative, carrageenan, guar gum, an alginate, a carbomer, a polyethylene glycol, a polyvinyl alcohol and xanthan gum. 
Farmaceutski pripravak u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak sadrži najmanje jedno sredstvo za povećavanje viskoznosti, koje se bira iz skupine koju čine polivinilpirolidon, celulozni derivat, kojeg se bira iz skupine koju čine hidroksietilceluloza, karboksimetilceluloza i hipromeloza, karagenan, guar guma, alginat, karbomer, polietilen-glikol, polivinil-alkohol i ksantanska guma, koje smanjuje ili sprječava postnazalno cijeđenje navedenog pripravka u ždrijelo prilikom intranazalne ili okularne primjene pripravka.
A pharmaceutical composition comprising a crystalline form of a compound of Formula XI substantially in the form of Form 2 characterized by an X-ray diffraction pattern having characterizing peaks at about 9.5 and 12.6 on the 2θ scale, in combination with an anti-tumor agent or a signal transduction inhibitor. 
Kristalni oblik spoja formule XI [image] bitno u obliku oblika 2, 2-(2-fluoro-4-jodofenilamino)-N-(2-hidroksietoksi)-1,5-dimetil-6-okso-1,6-dihidropiridin-3-karboksamid naznačen time da uzorkom rendgenske difrakcije koja ima karakterizirajuće šiljke na oko 9.5 i 12.6 na skali 2θ.
A composition according to any one of clauses 8 to 11, wherein the particles of weak acid, or of weakly-acidic buffer forming materials, are presented and act as carrier particles. 
Tableta prema bilo kojem od zahtjeva 3 do 6, pri čemu su čestice limunske kiseline predstavljene 1 ponašaju se kao čestice nosača.
The compound of any one of claims 1 to 3 or the pharmaceutical composition of claim 5 for use in the treatment or prevention of a condition selected from dementias, parkinsonism and movement disorders, acute or chronic pain, anxiety disorders, schizophrenia, mood disorders, endocrine and metabolic diseases, diabetes, disorders of the endocrine glands, hypoglycaemia, or cancers. 
Spoj prema bilo kojem od zahtjeva 1 do 3 ili farmaceutski sastav prema zahtjevu 5 za uporabu u liječenju ili sprječavanju stanja odabranog od demencija, parkinsonizma i poremećaja kretanja, akutne ili kronične boli, anksioznih poremećaja, šizofrenije, poremećaja raspoloženja, endokrinih 1 metaboličkih bolesti, dijabetesa, poremećaja endokrinih žlijezda, hipoglikemije ili rakova.
the third constituent is a polyhydroxyurethane (PHU) which is obtained by the covalent coupling of bis or poly cyclic carbonates (CC) and di or polyamines (PA) molecules, 
- < spomenuti treći sastojak je polihidroksiuretan (PHU) koji se dobiva kovalentnim uparivanjem bis ili poli cikličkih karbonata (CC) 1 di ili poliamin (PA) molekula.
wherein R1, R2 and R6 are as defined in claim 1 . 
(Va) pri čemu su R1, R2 1 R6 kao što su definirani u zahtjevu 3.
RA is 5 to 6-membered heteroaryl optionally substituted by 1, 2, or 3 substituents independently selected from RCy; or 
RA je 5 do 6-člani heteroaril izborno supstituiran sa 1, 2, ili 3 supstituenta nezavisno izabrana od RCy; ili
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a compound of general formula (I) and/or a salt or stereoisomer thereof as defined in claim 1 or 2. 
Farmaceutski pripravak, naznačen time da sadrži farmaceutski prihvatljiv nosač i farmaceutski učinkovitu količinu spoja opće formule (21) ifili njegove soli ili stereoizomera kao što je definirano u patentnim zahtjevima 1-6.
is selected from -CH2CH2R8b and -CR8a=CR8aR8b; wherein each R8a is independently selected from hydrogen, fluoro and C1-4alkyl; and R8b is selected from -C(O)OR9a, - C(O)NR9aR9b, -C(O)NHOR9a, -C(O)X2R9a and a 5-6 member heteroaryl selected from: wherein the dotted line indicates the point of attachment with -CH2CH2 or -CR8a=CR8a of R3; wherein X2 is C1-4alkylene; R9a and R9b are independently selected from hydrogen, C1-4alkyl, hydroxy-substituted-C1-4alkyl, halo-substituted-C1-4alkyl and -X4R10; wherein X4 is selected from a bond and C1-3alkylene; and R10 is a 4-6 member saturated ring containing 1 to 3 atoms independently selected from O, N and S; wherein said heteroaryl of R8b is unsubstituted or substituted with 1 to 3 groups independently selected from C1-4alkyl and C3-8cycloalkyl; 
2 m. pri čemu crtkana linija označava točku priključenja sa -CH>ŽCH, ili -CRa=CRes, of Rs; pri čemu X> je Cr aalkilen; Ro, i Ro su neovisno odabrani od sljedećih: vodik, C,.galkil, hidroksi-supstituirani-C,_galkil, halo-supstituirani-C,.galkil i "X4Ri9; pri čemu je X, odabran od veze i Crgalkilena; i Rig je 4-6-člani zasićeni prsten koji sadrži 1 do 3 atoma neovisno odabrana od O, N i S; pri čemu je navedeni heteroaril od Reg, nesupstituiran ili supstituiran sa 1 do 3 skupine neovisno odabrane od C,.alkila 1 C3 gcikloalkila;
A compound of claim 1 which is a compound of formula (IV) or a pharmaceutically acceptable salt thereof, wherein the variables R1, R2 and Y have the meaning as defined in claim 1. 
R2 > 7 (ID gdje varijable R1, R2 1 Y imaju isto značenje kao što je definirano u zahtjevu 1.
The immunogenic polypeptide any of claims 1-6, wherein the immunogenic polypeptide further contains a deletion relative to the E. coli AcfD (orf3526) protein which increases solubility of the immunogenic polypeptide as compared to the E. coli AcfD (orf3526) protein wherein the deletion is removal of substantially all of the N-terminal amino acids up to the gly-ser region, removal of all or a part of the N-terminal proline-rich repeat, or both. 
Imunogenski polipeptid prema bilo kojem od zahtjeva 1-6, naznačen time da imunogenski polipeptid nadalje sadrži brisanje relativno prema €. coli AcfD (orf3526) proteinu koje povećava topljivost imunogenskog polipeptida u odnosu na E. coli AcfD (0rf3526) protein pri čemu brisanje je uklanjanje značajno svih N-terminalnih amino kiselina do gly-ser regije, uklanjanje svih ili dijela N-terminalnih prolinom bogatih ponavljanja, ili oboje.
More preferred compositions comprise: artemether and a pharmaceutically-acceptable excipient selected the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage, and especially a composition consisting essentially of: artemether and a pharmaceutically-acceptable excipient selected the group consisting of: medium chain length triglycerides; short chain triglycerides; and omega-3-marine triglycerides, said composition formulated for transmucosal sublingual, buccal or nasal dosage. 
Kompozicija prema patentnom zahtjevu 1 naznačena time što se uglavnom sastoji od: artemetra ili arteetra; i farmaceutski prihvatljivog inertnog punitelja izabranog iz grupe koju čine: trigliderid tekući na 37*C; i trigliceridi srednje dužine lanca; pri čemu je navedena kompozicija formulirana za transmukozalnu subligvalnu, bukalnu ili nazalnu dozu.
storing in a database of the computing means pre-stored values of different sun exposure levels and temperature values and for each of said pre-stored values also having stored a corresponding gain control and gain modifier values, 
- < pohranjuje u računalnu bazu podataka prethodno empirijski utvrđene vrijednosti razina izloženosti suncu i temperaturnih vrijednosti te za svaku od spomenutih pohranjenih vrijednosti također ima pohranjenu odgovarajuću vrijednost kontrole pojačanja i modifikatora pojačanja pojačala, 1
A combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 for enhancing the antitumor effect of irinotecan hydrochloride hydrate in a solid cancer patient, wherein the combination drug containing trifluridine and tipiracil hydrochloride in a molar ratio of 1:0.5 is administered, using a reduced amount of trifluridine, at a dose in the range of 35 to 70 mg/m2/day, and irinotecan hydrochloride hydrate is administered at a dose in the range of 45 to 144 mg/m2/day. 
Kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 za primjenu u poboljšanju antitumorskog efekta irinotekan hidroklorid hidrata u liječenju pacijenta sa solidnim tumorom, gdje kombinirani lijek koji sadrži trifluridin i tipiracil hidroklorid u molarnom odnosu od 1:0.5 je administriran, primjenjujući smanjenu količinu trifluridina, u dozi u opsegu od 35 do 70 mg/m"/dan, i irinotekan hidroklorid hidrat je administriran u dozi u opsegu od 45 do 144 mg/m?/dan.
These compounds have the general formula I: 
PATENTNI ZAHTJEVI Spoj formule I:
The antibody or an antigen-binding fragment for use of claim 8, wherein the antibody is administered in combination with at least one therapeutic agent. 
Protutijelo ili njegov ulomak koji veže antigen za uporabu prema zahtjevu 19 ili 20, naznačen time što je barem jedno terapeutsko sredstvo paratiroidni hormonski analog.
A process for creating a mixed turf (1) as claimed in claim 13, wherein said natural grass (3) is obtained in a nursery and subsequently transplanted onto said turf (1). 
Postupak proizvodnje mješovitog travnjaka (1) prema zahtjevu 13, naznačen time da navedena prirodna trava (3) se priprema u rasadnicima i zatim se presađuje na navedeni travnjak (1).
In some embodiments, the compound is selected from the compounds delineated in Table 1 and/or the Examples. 
Spoj prema zahtjevu 1, pri čemu je spoj odabran od skupine koja se sastoji od ili njegova farmaceutski prihvatljiva sol, stereoizomer, 1/ili N-oksid.
a plunger capable of launching the lancet in a pricking direction, the lancet being in attachment to the plunger; 
klip (220) koji može pokrenuti lancete (400) u smjeru uboda, lancetu(400) u privitku do klipa (220);
Rand R'are each independently selected from the group consisting of: 
R i R’ su svaki neovisno odabrani iz skupine koja se sastoji od:
is C12-20-alkyl, and its enantiomers, diastereomers and salts. 
predstavlja C12-20-alkil, i njihovi enantiomeri, dijastereomeri i njihove soli.
The electricity supply control system according to any one of the preceding claims, wherein said control unit comprises a memory unit comprising a database including emission values associated with different types of energy sources, wherein said different parameters are type of energy source, and wherein one of said at least one predefined conditions is selecting the energy source with the lowest emission value retrieved from said database. 
Sustav za kontrolu električnog napajanja (100) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što navedena kontrolna jedinica (105) sadrži memorijsku jedinicu, koja sadrži bazu podataka koja sadrži vrijednosti emisije povezane s različitim oblicima izvora energije (101), gdje su navedeni različiti parametri oblik izvora energije, te gdje je jedan od navedenog najmanje jednog zadanog uvjeta odabir izvora energije s najnižom vrijednošću emisije preuzetog iz navedene baze podataka.
A valve as claimed in claim 3, wherein, in the saline position, the saline inlet (220) is connected to the outlet (230) via the secondary channel (320) and not connected to the primary channel (310). 
Ventil u skladu s patentnim zahtjevom 3, pri čemu je u položaju za fiziološku otopinu, dovod (220) fiziološke otopine povezan s izlazom (230) preko sekundarnog kanala (320) i nije povezan s primarnim kanalom (310).
represents alkyl, alkenyl, cycloalkyl, cycloalkenyl, alkynyl, alkoxy, haloalkyl, alkylthio, heterocycloalkenyl, heterocycloalkyl, aryl, alkylcarbonyl, heteroaryl, aryloxy, alkoxycarbonyl, hydroxyalkyl, amino, hydroxy, or carboxy; all of which are optionally substituted by one or more, same or different substituents selected from R10; 
predstavlja alkil, alkenil, cikloalkil, cikloalkenil, alkinil, alkoksi, haloalkil, alkiltio, heterocikloalkenil, heterocikloalkil, aril, alkilkarbonil, heteroaril, ariloksi, alkoksikarbonil, hidroksialkil, amino, hidroksi ili karboksi; gdje su svi oni izborno supsitituirani sa jednim ili više, istih ili različitih supstituenata izabranih od R10;
In some embodiments, compounds of the invention are partial agonists of the RUP25 receptor. 
U nekim oblicima, spojevi izuma su djelomični agonisti RUP25 receptora.
The biomorphic hydroxyapatite scaffold for use according to claim 13, wherein said long bone of the leg and arm is the tibia, metatarsus, fibula, femur, humerus or radius. 
Biomorfna hidroksiapatitna skela za primjenu u skladu sa patentnim zahtjevom 13, gdje navedena duga kost noge ili ruke je tibija, metatarzalna, fibula, femur, ramena kost ili palčana kost.
The locking device (1) according to claim 1, wherein the at least one sensor is configured to indirectly monitor an end position of the locking pin (9) in the locked and/or unlocked state. A locking method for locking a tool to a tool holder of a rotary drilling rig, the method comprising steps of: 
Zaporni postupak za zaključavanje alata u držač alata (3) od okretne opreme za bušenje koja obuhvaća najmanje jedan zaporni uređaj (1) prema bilo kojem od prethodnih zahtjeva, naznačen time, da obuhvaća sljedeće korake: spajanje alata na držač alata (3);
For example, the aerosol forming substance may be applied full strength or in a dilute solution by dipping, spraying, vapor deposition, or similar techniques. 
Na primjer, supstanca za formiranje aerosola može se primjeniti punom jačinom ili u razblaženoj otopini uranjanjem, prskanjem, deponiranjem pare ili sličnim tehnikama.
An article comprising the nonwoven fabric according to any one of claims 1 to 7, wherein said article is selected from construction products, consumer apparel, industrial apparel, medical products, home furnishings, protective products, packaging materials, cosmetic products, hygiene products, or filtration materials. 
Proizvod koji sadrži netkani materijal prema bilo kojem od zahtjeva 1 do 5, naznačen time da je navedeni proizvod odabran od građevinskih proizvoda, potrošačke odjeće, industrijske odjeće, medicinskih proizvoda, namještaja za dom, zaštitnih proizvoda, materijala za pakiranje, kozmetičkih proizvoda, higijenskih proizvoda ili materijala za filtriranje.
The crystalline sodium salt according to claim 2, having an X-ray powder diffraction pattern comprising peaks at 5.4, 6.5, 8.7, 11.9, 13.0, 18.2, 20.2 and 24.7 degrees 2θ (± 0.2 degrees 2θ) when measured using CuKa radiation. 
Kristalna natrijeva sol prema zahtjevu 2, naznačena time, da ima uzorak difrakcije praha X-zraka koji obuhvaća vršne vrijednosti na 5,4, 6,5, 8,7, 11,9, 13,0, 18,2, 20,2 1 24,7 stupnjeva 20 (+ 0,2 stupnjeva 20) kada se mjeri uporabom radijacije CuKa.
Transverse lines in form of sulci, limited proximally by slightly elevated ridges and affecting the surface of all nails at the corresponding level, have been described as retrospective indicators of a number of pathological status. 
Transverzalne linije u obliku žljebova, koje su proksimalno ograničene s nešto uzdignutim grebenima i utječu na površinu svih noktiju na odgovarajućoj razini, opisane su kao retrospektivni pokazatelji brojnih patoloških stanja.
The method of claim 1, further comprising the step of recrystallizing 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride to form Form A of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione hydrochloride. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što dodatno uključuje korak prekristaliziranja 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-il)piperidin-2,6-dion-hidroklorida; gdje 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-iI)piperidin-2,6-dion-hidroklorid može imati čistoću koja nije manja od 95%, težinski.
A conjugate comprising an oxyntomodulin derivative comprising the amino acid sequence of SEQ ID NO: 24, 25, or 26, an immunoglobulin Fc region, and a non-peptidyl polymer, wherein the non-peptidyl polymer covalently links the oxyntomodulin derivative and the immunoglobulin Fc region. 
Konjugat koji sadrži derivat oksintomodulina koji sadrži aminokiselinski slijed SEQ ID NO: 24, 25 ili 26, Fc regiju imunoglobulina i nepeptidilni polimer, naznačen time da nepeptidilni polimer kovalentno povezuje derivat oksintomodulina i Fc regiju imunoglobulina.
The composition of claim 23, wherein the isolated keratin proteins are water insoluble B-keratin proteins. 
Sastav u skladu sa zahtjevom 23, naznačen time, što su izolirani keratin proteini vodno netopljivi B-keratin proteini.